42C IX Biopharma
- 0.024
- 0.0000.00%
IX Biopharma News
General Announcement-Press Release - iXB 401 Achieves 20x Higher Bioavailability Than Rybelsus in Preclinical Study
General Announcement-Minutes of Extraordinary General Meeting Held on 17 October 2024
General Announcement-Minutes of Annual General Meeting Held on 17 October 2024
General Announcement-Formation of the Audit and Risk Committee and Reconstitution of the Board Committees
IX Biopharma: REPL-Extraordinary/ Special General Meeting-Voluntary
IX Biopharma: REPL-Annual General Meeting-Voluntary
General Announcement-Press Release - iX Biopharma Appoints Dr. Brian Kennedy as New Scientific Advisor
IX Biopharma: Extraordinary/ Special General Meeting-Voluntary
Change - Announcement of Cessation-Retirement of Independent Director
IX Biopharma: Annual General Meeting-Voluntary
General Announcement-Press Release - Business and Drug Development Updates - Wafermine and iXB 401
General Announcement-Press Release - New Study Demonstrates that SL-NAD+ Delivers NAD+ into Cells
General Announcement-Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients
REPL-General Announcement-Issue and Listing of the Rights Shares and the Warrants
General Announcement-Issue and Listing of the Rights Shares and the Warrants
IX Biopharma: General Announcement-Notice From Undertaking Shareholder Anson Properties Pte. Ltd.
IX Biopharma: General Announcement-Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial
IX Biopharma: General Announcement-Proposed Renounceable Non-Underwritten Rights Cum Warrants Issue-Despatch of Notification and Forms
IX Biopharma: General Announcement-Notice of Adjustment to Conversion Price of 9% Convertible Bonds Principal Amount S$2 Million
IX Biopharma: General Announcement-Update For Shareholders
No Data